Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 2/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | NFKB2 | Q00653 | 1/20 | 1.00 |
| ▸ | RELA | Q04206 | 1/20 | 1.00 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.63 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | PPARG | P37231 | 2/20 | 0.62 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.59 |
| ▸ | OXER1 | Q8TDS5 | 1/20 | 0.56 |
| ▸ | CMKLR1 | Q99788 | 1/20 | 0.56 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.53 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.53 |
| ▸ | GAPDH | P04406 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1480564 | 1.00 | FPR2 (1.00) | FPR2NFKB1NFKB2RELALTB4R2 | |
| Lipoxin A4 SCHEMBL19668574 | 1.00 | FPR2 (1.00) | FPR2NFKB1NFKB2RELALTB4R2 | |
| SCHEMBL3299698 | 1.00 | FPR2 (1.00) | FPR2NFKB1NFKB2RELALTB4R2 | |
| SCHEMBL2346223 | 1.00 | FPR2 (1.00) | FPR2NFKB1NFKB2RELALTB4R2 | |
| Lipoxin A4 SCHEMBL3302874 | 1.00 | FPR2 (1.00) | FPR2NFKB1NFKB2RELALTB4R2 | |
| Lipoxin A4 SCHEMBL1691709 | 1.00 | FPR2 (1.00) | FPR2NFKB1NFKB2RELALTB4R2 | |
| SCHEMBL12102087 | 1.00 | FPR2 (1.00) | FPR2NFKB1NFKB2RELALTB4R2 | |
| Lipoxin A4 SCHEMBL3408493 | 1.00 | FPR2 (1.00) | FPR2NFKB1NFKB2RELALTB4R2 | |
| Lipoxin A4 SCHEMBL8743448 | 1.00 | FPR2 (1.00) | FPR2NFKB1NFKB2RELALTB4R2 | |
| SCHEMBL5162003 | 1.00 | FPR2 (1.00) | FPR2NFKB1NFKB2RELALTB4R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3544684-B1 | PERSONALIZED METABOLOMIC PROFILING OF SPECIALIZED PRO-RESOLVING MEDIATORS | BRIGHAM & WOMENS HOSPITAL INC (US) | 2025-09-17 | — | — | EP | claimed |
| EP-4499060-A1 | SPECIALIZED PRO-RESOLVING LIPID MEDIATORS FOR TREATING LONG COVID-19 | Chemo Research, S.L. (ES) | 2025-02-05 | — | — | EP | claimed |
| US-20240165069-A1 | METHODS FOR TREATING DYSGEUSIA AND OTHER LINGERING SYMPTOMS ASSOCIATED WITH SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 INFECTIONADN CORONAVIRUS DISEASE 2019 | NOCENDRA, INC | 2024-05-23 | — | — | US | claimed |
| EP-4255412-A1 | SPECIALIZED PRO-RESOLVING LIPID MEDIATORS FOR TREATING PCOS | Chemo Research, S.L. (ES) | 2023-10-11 | — | — | EP | claimed |
| WO-2023180569-A1 | SPECIALIZED PRO-RESOLVING LIPID MEDIATORS FOR TREATING LONG COVID-19 | CHEMO RESEARCH , S.L. (ES) | 2023-09-28 | — | — | WO | claimed |
| WO-2022178249-A1 | METHOD FOR TREATING DYSGEUSIA AND OTHER SYMPTOMS ASSOCIATED WITH COVID-19 | NOCENDRDA, INC. (US) | 2022-08-25 | — | — | WO | claimed |
| WO-2022117828-A1 | SPECIALIZED PRO-RESOLVING LIPID MEDIATORS FOR TREATING PCOS | CHEMO RESEARCH , S.L. (ES) | 2022-06-09 | — | — | WO | claimed |
| CN-108366600-B | Process for the preparation and stabilization of emulsions with omega-3 by an equiaxed crystalline network of cellulose derivatives | 索吕泰克斯纳有限公司 | 2022-04-29 | — | — | CN | claimed |
| US-12478593-B2 | Formulations for hair growth | JENIVISION INC. (US) | 2025-11-25 | — | — | US | disclosed |
| EP-3544684-B1 | PERSONALIZED METABOLOMIC PROFILING OF SPECIALIZED PRO-RESOLVING MEDIATORS | BRIGHAM & WOMENS HOSPITAL INC (US) | 2025-09-17 | — | — | EP | disclosed |
| US-20250255842-A1 | SPECIALIZED PRO-RESOLVING LIPID MEDIATORS FOR TREATING LONG COVID-19 | SOLUTEX GC, S.L. (ES) | 2025-08-14 | — | — | US | disclosed |
| US-12274686-B2 | Specialized pro-resolving mediators (SPMs) as melanocyte growth promoter and pro-survival factors and uses thereof | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2025-04-15 | — | — | US | disclosed |
| EP-4499060-A1 | SPECIALIZED PRO-RESOLVING LIPID MEDIATORS FOR TREATING LONG COVID-19 | Chemo Research, S.L. (ES) | 2025-02-05 | — | — | EP | disclosed |
| US-20240269170-A1 | Treatment of Inflammatory Conditions or Diseases | UNIV LONDON QUEEN MARY (GB) | 2024-08-15 | — | — | US | disclosed |
| US-7227031-B2 | Aspirin-triggered lipoxins as modulators of diseases associated with polymorphoneutrophil inflammation; antiinflammatory agents | THE BRIGHAM AND WOMEN'S HOSPIAL, INC. (US) | 2007-06-05 | — | — | US | disclosed |
| EP-1586550-A1 | Lipoxin compounds and their use | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2005-10-19 | — | — | EP | disclosed |
| US-20050192350-A1 | Prevention of neutrophil recruitment | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2005-09-01 | — | — | US | disclosed |
| EP-1163204-B1 | LIPOXIN COMPOUNDS AND THEIR USE | BRIGHAM & WOMENS HOSPITAL (US) | 2005-08-31 | — | — | EP | disclosed |
| US-6659282-B2 | Antiinflammatory lipoxing derivatives | BRIGHAM AND WOMEN'S HOSPITAL | 2003-12-09 | — | — | US | disclosed |
| US-6433202-B1 | ANTIINFLAMMATORY AGENTS | BRIGHAM AND WOMEN'S HOSPITAL | 2002-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12274686-B2 | Specialized pro-resolving mediators (SPMs) as melanocyte growth promoter and pro-survival factors and uses thereof | ALOX15B, ALOX15, ALOX12 | FPR2 32/4885NFKB1 653/4885NFKB2 784/4885 |
| US-20050192350-A1 | Prevention of neutrophil recruitment | ALOX15, ALOX15B, ALOX5 | FPR2 26/4885NFKB1 438/4885NFKB2 635/4885 |
| US-20240165069-A1 | METHODS FOR TREATING DYSGEUSIA AND OTHER LINGERING SYMPTOMS ASSOCIATED WITH SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 INFECTIONADN CORONAVIRUS DISEASE 2019 | LTA4H, LTB4R2, LTB4R | FPR2 361/4885NFKB1 3461/4885NFKB2 3421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.